Related Experiment Videos
[Estrogens and breast cancer].
Anales De La Real Academia Nacional De Medicina
|February 24, 2001
Summary
Substitutive Hormonal Therapy (SHT) with estrogens during menopause should be limited to five years and not given to women over 60. Combined SHT increases breast cancer risk and is not recommended for certain patient groups.
Area of Science:
- Endocrinology
- Oncology
- Women's Health
Context:
- Estrogen's role in breast cancer genesis is complex and context-dependent.
- Menopausal hormone therapy (MHT) is widely used for symptom management.
- Previous studies have shown mixed results regarding MHT and cancer risk.
Purpose:
- To review the role of estrogen in breast cancer development.
- To provide evidence-based recommendations for the safe use of SHT during menopause.
Summary:
- Estrogen therapy for menopause should not exceed five years or be used in women over 60.
- Combined estrogen-progesterone SHT protects against endometrial cancer but elevates breast cancer risk.
- Contraindications for SHT include hypertension with calcium blocker use and a family history of breast cancer.
Impact:
- Informs clinical practice regarding menopausal hormone therapy guidelines.
- Aims to reduce the risk of hormone-related cancers in postmenopausal women.
- Highlights the importance of personalized risk assessment for SHT prescription.